Peter Dehnel, MD, CentraCare Health System
By Karen Blum
Las Vegas—In homage to Charles Dickens, you might say it’s the best of times and worst of times for patients with rare or orphan diseases.
There is an expanding portfolio of drug options for these patients, as well as increased longevity, decreased comorbidities, less hospitalization and closer to near normal health for numerous conditions, “which are wonderful promises for people who have awful diseases,” said